Table 3. Summary of clinical, laboratory, and imaging characteristics, as well as information about the need for oxygen therapy.
| Ma et al. 16 | Sun et al. 17 * | Liu et al. 18 | Zhong et al. 19 | Dodi et al. 20 | |
|---|---|---|---|---|---|
| Number of children | 115 | 8 | 4 | 9 | 14 |
| Age group (years) | --- | 0-15 | 0-9 | 0-12 | --- |
| Male/female | 73/42 | 6/2 | 2/2 | 4/5 | 9/5 |
| Location | China | China | China | China | Italy |
| Period | --- |
|
--- | --- |
|
| Fever | 29 (25.2%) | 6 (75%) | 3 (75%) | 2 (22.2%) | 14 (100%) |
| Cough | 47 (40.9%) | 6 (75%) | 3 (75%) | 5 (55.5%) | 5 (35.7%) |
| Myalgia/fatigue | --- | 1 (12.5%) | 1 (25%) | 3 (21.4%) | |
| Diarrhea, nausea, and/or vomiting | --- | 4 (50%) | --- | 0 | 2 (14.3%) |
| Odynophagia | --- | --- | --- | --- | 7 (50%) |
| Dyspnea/tachypnea | --- | 8 (100%) | --- | --- | --- |
| Abnormality on chest CT | 49 (42.6%) | 8 (100%) | 3 (75%) | --- | --- |
| Leukocytosis | --- | --- | 0 | 1 (11.1%) | --- |
| Neutropenia | --- | --- | 2 (50%) | 5 (55.5%) | --- |
| Lymphocytosis | --- | --- | 2 (50%) | 2 (22.2%) | --- |
| Lymphopenia | --- | --- | 1 (11.1%) | 1 (7.1%) | |
| Leukopenia | --- | --- | 1 (25%) | 1 (11.1%) | --- |
| Increased AST and ALT | 11 (9.6%) | 4 (50%) | --- | --- | |
| Increased CK/CK-MB | 34 (29.6%) | --- | --- | --- | |
| Increased CRP | --- | 5 (62.5%) | 1 (25%) | 9 (100%) | --- |
| Increased procalcitonin | --- | 5 (62.5%) | 0 | --- | |
| Increased ESR | --- | --- | --- | --- | |
| Need for oxygen | 3 (2.6%) | 8 (100%)* | 0 | 0 | 0 |
CT: computed tomography; AST: aspartate transaminase; ALT: alanine transaminase; CK: creatine kinase: CK-MB: CK MB isoenzyme; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate.
*Study only analyzed children with a severe presentation of COVID-19.